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Abstract 
To establish the role of co-overexpression of
bcl-2  and  c-myc  protooncogenes  in  uterine
cervix carcinogenesis, we examined 138 tissue
samples of low grade cervical squamous intraep-
ithelial lesions (SIL), high grade SIL, portio vagi-
nalis uteri (PVU) carcinoma in situ and PVU
invasive carcinoma, stage IA-IIA (study group)
and 36 samples without SIL or malignancy (con-
trol group). The expression of bcl-2 and c-myc
was  detected  immunohistochemically  using  a
monoclonal  antibody.  Fisher’s  exact  test
(P<0.05) was used to assess statistical signifi-
cance.  Overexpression  of  bcl-2  was  found  to
increase in direct relation to the grade of the
cervical lesions. High sensitivity was of great
diagnostic significance for the detection of these
types of changes in the uterine cervix. On the
basis of high predictive values it can be said that
in patients with bcl-2 overexpression there is a
great possibility that they have premalignant or
malignant  changes  in  the  uterine  cervix.  Co-
overexpression  of  bcl-2  and  c-myc  oncogenes
was found only in patients with PVU invasive
carcinoma (6/26-23.0%). Statistically significant
difference was not found in the frequency of co-
overexpression in patients with PVU invasive
carcinoma  in  relation  to  the  control  group
(Fisher’s test; P=0.064). The method's sensitivi-
ty of determining these oncogenes with the aim
of detecting PVU invasive carcinoma was 23%,
while specificity was 72.2%. On the basis of high
predictive values (100%), speaking in statistical
terms, it can be concluded that all patients with
co-overexpression of bcl-2 and c-myc oncogenes
will have PVU invasive carcinoma. We confirmed
in our research that co-overexpression of bcl-2
and c-myc oncogenes was increased only in PVU
invasive carcinoma. However, a more extensive
series  of  samples  and  additional  tests  are
required to establish the prognostic significance
of bcl-2 and c-myc co-overexpression in cervical
carcinogenesis.
Introduction
Squamous  cell  carcinoma  of  the  uterine
cervix is currently one of the most common
malignancies in women worldwide. In search-
ing  ways  of  prevention,  early  diagnosis  and
effective  treatment  of  premalignant  lesions
and malignant tumors of the uterine cervix,
molecular-genetic researches played a signifi-
cant role in the last few years.
Alterations at the genetic or protein level of
the protooncogenes result in oncogenic con-
version and impaired cellular growth control
mechanisms, causing tumor development.1
Analysis of oncogenes expression in human
cancer is increasingly important to gain a bet-
ter insight in the process of tumorigenesis and
identify  new  markers  for  early  diagnosis  of
malignant  transformation.  Abnormal  expres-
sion of different cellular oncogenes in various
cancers  assessed  by  hybridization  and
immunological techniques has been previous-
ly reported.2 The results of these analyses do
not appear to be of any early diagnostic value
since oncogene expression is, in general, only
demonstrable  in  tumors  that  can  already  be
classified as malignant.
The  key  difference  between  normal  and
malignant cell is in a subtle change of specific
genes  that  control,  by  their  products,  the
processes of growth, division and differentia-
tion of a cell and are called protooncogenes.
These genes that are present in the genotype
of  every  normal  cell  possess  the  oncogenic
potential because their disturbed expression
may lead to malignant transformation.
The bcl-2 family of related proteins is one of
the key regulators of the apoptotic process. It
consists of two opposing groups of proteins:
death  antagonists  (bcl-2,  bcl-XL,  Mcl-1)  and
death agonists (bax, bak, bcl-XS).3 Apoptosis
occurs  through  competing  dimerization
between the two protein groups. The relative
proportions  of  which  ultimately  control  the
sensitivity or resistance of cells to apoptotic
stimuli. Overexpression of bcl-2 and bax and
their prognostic significance have been report-
ed in several epithelial cancers.4 However, the
data on squamous cell carcinoma of the uter-
ine cervix are limited and the results are con-
flicting.2,5 In vitro studies have also shown that
bcl-2 overexpression prolonged cell survival in
cell  culture  studies.6 Therefore,  an  in  vivo
study on the association between these apop-
tosis regulatory proteins may be a prerequisite
for the complete understanding of the molecu-
lar  pathogenesis  underlying  cervical  cancer
development. 
Mitochondrial and cell-surface death recep-
tor-mediated apoptosis are the two principal
pathways  leading  to  programmed  cell  death.
The mitochondrial pathway is thought to play a
major role in response to cancer treatments
and is mediated by the bcl-2 family proteins.7
More  than  20  members  of  this  family  have
been described so far in humans. A positive
ratio between pro- and antiapoptotic bcl-2 fam-
ily  members  leads  to  cytochrome-C  release
from  mitochondria,  which  triggers  the  final
execution of cell death by the caspase cascade. 
The c-myc gene belongs to the myc family
that includes b-myc, l-myc, n-myc and s-myc.
However,  only  c-myc,  l-myc  and  n-myc  have
neoplastic potential.8 The ability of myc to pro-
mote cell proliferation indicates that its dereg-
ulation  leads  to  deregulated  DNA  synthesis
and  genomic  instability.9 Deregulated  myc
expression  is  linked  to  increasing  in  both
cyclin A and cyclin E levels.10 In vitro and in
vivo data indicate that increased expression of
c-myc blocks differentiation and enhances pro-
liferative  and  apoptotic  activity.11 Chlamydia
trachomatis and HPV high-risk types may con-
tribute to neoplastic changes in the transfor-
mation of the uterine cervix and also might
modulate expression of c-myc oncogene.12
Overexpression  of  c-myc  was  frequently
found in advanced stages of cervical cancers
and was shown to be associated with tumor
progression.13,14 Moreover, it has been shown
in experimental tumor systems that increased
expression of bcl-2 and c-myc can cooperate in
tumorigenesis.14,15
Materials and Methods
This prospective study was carried out dur-
ing  2008  and  2009,  at  the  Department  of
Obstetrics and Gynecology, Faculty of Medicine
and the experimental part was performed at
the Laboratory for Experimental and Clinical
Immunology of the Faculty of Medicine and at
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the  Immunological  Laboratory  of  the  Public
Health  Institute,  Kragujevac,  Serbia.  From
patients  operated  at  the  Department  of
Obstetrics and Gynecology because of prema-
lignant and/or malignant changes of the uter-
ine cervix, some tissue sections were taken
from  the  operative  material  (hysterectomy,
punch biopsy or conization) for pathological
verification and used for this research.  The
control group consisted of 36 females in whom
ambulatory biopsy of the uterine cervix was
performed (Papanicolaou test was indicated)
and  where  malignant  changes  or  squamous
intraepithelial lesions (SIL) were not found by
histopathology (cervicitis chronica of mild to
moderate degree). The study group consisted
of 32 patients with the pathological diagnosis
of low grade SIL, 22 with high grade SIL, 22
with PVU carcinoma in situ and 26 with PVU
invasive carcinoma, stage IA-IIA. Bcl-2 and c-
myc oncogene expression followed in patients
in the study and the control group. Co-overex-
pression of this oncogene was observed as the
way of detection of premalignant and malig-
nant changes in the uterine cervix. Cryostat
sections were sent for intraoperative diagno-
sis.  Extra  sections  of  cervical  lesions  were
snap-frozen in liquid nitrogen and stored at 
-70°C until used for immunohistochemistry.
Bcl-2  (Anti-Bcl-2ʱ (Ab-1)  Mouse  mAb
(100/D5),  Calbiochem,  Oncogene  Research,
Cambridge, MA, USA) and c-myc (Anti-c-Myc
(Ab-1) Mouse mAb (9E10), Calbiochem) mon-
oclonal antibody was used, which was diluted
with phosphate buffered saline (PBS, pH 7.2). 
Four-micrometer frozen sections were fixed
in 100% acetone for 5 min and the endogenous
peroxidase activity was quenched by 10 min
incubation  in  0.5%  hydrogen  peroxide.  For
monoclonal antibody bcl-2 and c-myc (concen-
tration of 1 ʼg/mL) incubation with primary
antibody  was  carried  out  overnight  at  4°C.
Sections of bcl-2 positive lymphoid tissue were
used  as  positive  controls.  Sections  of  c-myc
positive lung carcinoma were used as positive
controls.  For  negative  controls,  the  samples
were taken through the procedure with omis-
sion of the primary antibody. Slides were eval-
uated  by  two  of  the  authors,  unaware  of
immunohistochemical or clinical data using a
semiquantitative  method  on  a  Zeiss
AXIOSKOP 2 light microscope. The percentage
of  immunopositive  cells  in  representative
areas of the sections was assessed. The inten-
sity of immunostaining was divided into 4 cat-
egories,  namely  i)  negative  (0-5%)  and  ii)
1+(5-25%); iii) positive 2+(25-50%) and iv)
3+ (50-100%). Tissue sections from the opera-
tive material or material taken by biopsy were
taken  after  obtaining  informed  consent  of
patients in accordance with the Declaration of
Helsinki and recommendations of the World
Health Organization (WHO) for experiments
on human material and after getting approval
of the Ethics Committee.
Statistics 
Based on the frequency of the lesions found,
patients were split into 4 subgroups and 2ﾥ2
contingency tables were formed and specificity
and sensitivity were calculated. Also, based on
the  receiver  operating  characteristic  (ROC)
curve, which represents the relation between
specificity and sensitivity, the discrimination
power of the test was determined. Differences
between  groups  were  considered  significant
(Fisher’s exact test) at P<0.05. By establishing
sensitivity and specificity of the test, the relia-
bility of these analyses, could be the subject of
scientific investigation as one of the factors in
the prognosis of premalignant lesions of the
uterine  cervix,  in  the  course  of  future
researches.
Results
Table 1 and Figure 1 show the expression
levels of bcl-2 oncogene in the study and con-
trol group. Overexpression of bcl-2 was present
in 5.6% (mean±SD = 9.61±13.27) of women in
the control group and in 25.0% (mean±SD=
20.44±27.69) (of patients with low grade SIL.
Analysis of frequency of patients with positive
findings of bcl-2 oncogene revealed no statisti-
cal differences when control and low grade SIL
groups  were  evaluated  (Fisher’s  exact  test,
P=0.164).  On  the  basis  of  the  frequency  of
patients with bcl-2 overexpression, a 2ﾥ2 table
of contingency was formed (Table 2), in which
sensitivity and specificity were calculated. The
sensitivity of determining bcl-2 as a method
for detection of low grade SIL was 25.0% and
specificity was 94.4% (Figure 2). The positive
predictive value was 80.27%, which means that
this percentage of patients with bcl-2 overex-
pression may be expected to harbor low grade
SIL in the cervix. The negative predictive value
was 94.8%, meaning that this percentage of
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Figure 1. Percentage of positive and nega-
tive bcl-2 expression.
Figure 2. Receiver operating characteristic
curve for bcl-2 overexpression in patients
with  low  grade  squamous  intraepithelial
lesions.
Table 1. Expression of bcl-2 in the control and study groups.
bcl-expression Control  Low grade High grade PVU in situ PVU invasive
expression group, SIL, SIL, carcinoma, carcinoma,
n (%) n (%) n (%) n (%) n (%)
Negative (-) 20/36 (55.5) 16/32 (50) 8/22 (36.3) 8/22 (36.3) 8/26 (30.8)
Negative (1+) 14/36 (38.9) 8/32 (25.0) 2/22 (9.1) 4/22 (18.2) 6/26 (23.1)
Positive (2+) 2/36 (5.6) 2/32 (6.2) 8/22 (36.3) 6/22 (27.3) 8/26 (30.8)
Positive (3+) 0/36 (0) 6/32 (18.8) 4/22 (18.2) 4/22 (18.2) 4/26 (15.3)
SIL, squamous intraepithelial lesions; PVU, portio vaginalis uteri. 
Table 2. Table of contingency (low grade squamous intraepithelial lesions).
Test Disease present Disease absent Total
(low grade SIL) (control group)
bcl-2 overexpression 8 (P=0.164) 2 10
bcl-2 negative 24 34 58
Total 32 36 68
SIL, squamous intraepithelial lesions.[page 46] [European Journal of Histochemistry 2011; 55:e8]
patients with bcl-2 negative expression exis-
tence of this type of change is not expected.
Table 1 and Figure 1 show that bcl-2 overex-
pression was present in 5.6% of women in the
control  group  and  in  54.6%  (mean±SD=
27.27±21.89) of patients with high grade SIL
(Fisher’s exact test, P=0.006; Figure 3). The
sensitivity of determining bcl-2 for detecting
high grade SIL changes was 54.6% and speci-
ficity was 94.4% (Table 3 and Figure 4).
Regarding the obtained values of sensitivity
and  specificity,  the  discrimination  power  of
overexpression of this oncogene with the aim
of  determining  the  existence  of  changes  of
this type was greater than the discrimination
power  of  negative  expression  in  the  control
group.  The  positive  predictive  value  in  high
grade SIL changes was 85.89% and the nega-
tive predictive value was 77.21%. 
Table 1 and Figure 1 show that bcl-2 overex-
pression was present in 5.6% of patients in the
control  group  and  in  45.5%  (mean±SD=
6.27±7.04) of patients with PVU carcinoma in
situ (Fisher’s exact test, P=0.018; Figure 5).
The sensitivity of this oncogene for diagnosing
this type of lesions was 45.5% and specificity
was 94.2% (Table 4 and Figure 6). The positive
predictive value was 74.64% and the negative
predictive  value  was  67.98%.  Table  1  and
Figure 1 show that bcl-2 overexpression was
present in 5.6% of patients in the control group
and  in  46.1%  (mean±SD=  22.15±23.99)  of
patients  with  PVU  invasive  carcinoma
(Fisher’s exact test, P=0.012; Figure 7). The
sensitivity  and  specificity  of  the  test  were
46.2%  and  94.4%,  respectively  (Table  5  and
Figure 8), and the positive and negative pre-
dictive values were 85.84% and 70.80%, respec-
tively. Table 6 and Figure 9 show co-expression
levels of bcl-2 and c-myc oncogenes in the con-
trol  and  in  the  experimental  group  (6/26-
23.0%; (bcl-2 – mean±SD=51.67±20.17; c-myc
- mean±SD=43.33±22.29). Co-overexpression
of c-myc was only found in patients with PVU
invasive carcinoma (Figure 10).
Analysis of frequency of patients with posi-
tive  findings  of  bcl-2  and  c-myc  oncogenes,
revealed no statistical differences (P=0.064)
when  control  and  PVU  invasive  carcinoma
groups  were  evaluated.  None  of  the  control
patients exhibit co-overexpression of bcl-2 and
c-myc,  while  23%  of  the  patients  with  PVU
invasive carcinoma showed co-overexpression
of bcl-2 and c-myc oncogenes. The method's
Original paper
Table 7. Table of contingency (portio vaginalis uteri invasive carcinoma).
Test Disease present Disease absent Total
(PVU invasive carcinoma) (control group)
bcl-2 and c-myc co-overexpression 6 (P=0.064) 06
bcl-2 and c-myc negative 20 36 56
Total 26 36 62
PVU, portio vaginalis uteri.
Table 6. Co-expression of bcl-2 and c-myc in the control and study groups.
bcl-2 and c-myc Control  Low grade High grade PVU in situ PVU invasive
co-expression group, SIL, SIL, carcinoma, carcinoma,
n (%) n (%) n (%) n (%) n (%)
Negative (-) 28/36 (77.8) 24/32 (75) 16/22 (72.8) 18/22 (81.9) 12/26 (46.2)
Negative (1+) 8/36 (22.2) 8/32 (25.0) 6/22 (27.2) 4/22 (18.1) 8/26 (30.8)
Positive (2+) 0/36 (0) 0/32 (0) 0/22 (0) 0/22 (0) 2/26 (7.7)
Positive (3+) 0/36 (0) 0/32 (0) 0/22 (0) 0/22 (0) 4/26 (15.3)
SIL, squamous intraepithelial lesions; PVU, portio vaginalis uteri. 
Table 5. Table of contingency (portio vaginalis uteri invasive carcinoma).
Test Disease present Disease absent Total
(PVU invasive carcinoma) (control group)
bcl-2 overexpression 12 (P=0.012) 2 14
bcl-2 negative 14 34 48
Total 26 36 62
PVU, portio vaginalis uteri.
Table 3. Table of contingency (high grade squamous intraepithelial lesions).
Test Disease present Disease absent Total
(high grade SIL) (control group)
bcl-2 overexpression 12 (P=0.006) 2 14
bcl-2 negative 10 34 44
Total 22 36 58
SIL, squamous intraepithelial lesions.
Table 4. Table of contigency (portio vaginalis uteri carcinoma in situ).
Test Disease present Disease absent Total
(PVU carcinoma in situ) (control group)
bcl-2 overexpression 10 (P=0.018) 2 12
bcl-2 negative 12 34 46
Total 22 36 58
PVU, portio vaginalis uteri.
Figure 3. Bcl-2 overexpression (3+) in high
grade squamous intraepithelial lesions.
Figure 4. Receiver operating characteristic
curve for bcl-2 overexpression in patients
with high grade squamous intraepithelial
lesions.[European Journal of Histochemistry 2011; 55:e8] [page 47]
sensitivity of determining this oncogene with
the aim of detecting PVU invasive carcinoma
was 23% while specificity was 72.2%. On the
basis of the frequency of patients with bcl-2
and  c-myc  co-overexpression,  a  2x2  table  of
contingency was formed in which sensitivity
and  specificity  was  calculated  (Table  7).  On
the basis of the obtained values of sensitivity
and specificity, discrimination power of nega-
tive expression in patients with normal find-
ings in the cervix was greater than discrimina-
tion power of co-overexpression of this onco-
gene, with the aim of determining the exis-
tence of change of this type (Figure 11). The
positive predictive value was 100% which, sta-
tistical wise, means that PVU invasive carcino-
ma may be expected in all patients with co-
overexpression of bcl-2 and c-myc. However,
the substantiation of the claim requires much
more extensive research. The negative predic-
tive value was 64.34%, implying that the exis-
tence of this type of change is not expected at
this percentage of patients with negative co-
expression of bcl-2 and c-myc oncogene. 
Discussion
This study evaluated the expression of bcl-2
and  c-myc  oncogenes  in  a  range  of  tissues
obtained from normal, dysplastic and neoplas-
tic conditions of the cervix, in an attempt to
elucidate the expression of this oncoprotein in
uterine  cervix  premalignant  and  malignant
lesions. Bcl-2 is an oncogene that has been
investigated for prognostic significance in var-
ious malignancies, including carcinoma of the
cervix.16-18 Up to now, conflicting results have
been obtained. Bcl-2 has been shown in some
studies to be an independent predictor of poor
prognosis in carcinoma of the cervix.19 On the
other hand, other studies have revealed no sta-
tistically significant correlation with adverse
outcome.20
The conflicting results may be due to differ-
ences in institutional treatment standards and
to varied subjective interpretations of staining
intensity  and  distribution  between  centers.
Since staining is judged on a continuum, dif-
ferences  in  institutional  cut-off  determina-
tions for positive staining may also affect the
correlation with clinicopathological results.
Cheung  et  al.,  in  their  analysis  of  44
patients with cervical adenocarcinoma, found
that increased expression of bcl-2 was correlat-
ed with a poorer prognosis.21 The absence of
correlation between clinical prognosis and bcl-
2 expression was instead described by Jain et
al.22 In  our  study,  no  statistically  significant
difference was found in the frequency of over-
expression of bcl-2 between the control group
and patients with low grade SIL. However, sta-
tistically significant difference was found in
the  frequency  of  overexpression  in  patients
with high grade SIL, PVU carcinoma in situ
and PVU carcinoma invasive in relation to the
control group. High sensitivity values speak in
favor of great diagnostic significance for the
detection of these types of changes in the uter-
ine cervix. On the basis of high predictive val-
ues, it can be said that, in patients with over-
expression of bcl-2 oncogene, there is a great
possibility  that  they  have  premalignant  or
malignant changes in the uterine cervix.
The c-myc oncogene is known to regulate
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Figure 7. bcl-2 overexpression (3+) in por-
tio vaginalis uteri invasive carcinoma.
Figure 9. Percentage of positive and nega-
tive bcl-2 and c-myc co-expression.
Figure  8.  Receiver  operating  characteristic
curve for bcl-2 overexpression in patients with
portio vaginalis uteri invasive carcinoma.
Figure  10.  C-myc  overexpression  (3+)  in
portio vaginalis uteri invasive carcinoma. 
Figure 11. Receiver operating characteristic
curve  for  bcl-2  and  c-myc  co-overexpres-
sion in patients with portio vaginalis uteri
invasive carcinoma.
Figure 6. Receiver operating characteristic
curve  for  bcl-2  overexpression  in  patients
with portio vaginalis uteri carcinoma in situ.
Figure 5. Bcl-2 overexpression (3+) in por-
tio vaginalis uteri carcinoma in situ.[page 48] [European Journal of Histochemistry 2011; 55:e8]
neoplastic  development  and  apoptotic  cell
death. Myc protein is widely distributed in dif-
ferent tissues and is predominantly localized
to nuclei of cells where its positivity related to
proliferation rate.23
Bcl-2 at high concentrations protects cells
apoptosis induced by c-myc. However, the asso-
ciations of these proteins and the correlation
of their expression and the prognosis of cancer
are still controversial. Cooperation between c-
myc and bcl-2 in the lymphoid tumors has been
demonstrated in double transgenic mice.24
Jinyoung et al. found that overexpression of
c-myc and bcl-2 plays a role as prognostic fac-
tor in pulmonary adenocarcinomas.25
The positive role of c-myc in promoting cell
proliferation places this oncogene at the head
of  bcl-2  partners  for  metastatic  progression
and lymph node involvement of small and well
differentiated  breast  tumors,  because  bcl-2
may also act as an effective suppressor of the
apoptotic action of c-myc, without affecting its
ability to promote cell proliferation.26 Liu et al.
noted  a  significant  positive  relationship
between bcl-2 and c-myc in female genital tract
sarcomas.27
In our study, co-overexpression of bcl-2 and
c-myc oncogenes was found only in patients
with  PVU  invasive  carcinoma  (3/13-23.0%).
Analysis of frequency of patients with positive
findings of bcl-2 and c-myc, revealed no statis-
tical  significant  differences  (P=0.064)  when
control  and  PVU  invasive  carcinoma  groups
were  evaluated.  The  method's  sensitivity  of
determining this oncogenes with the aim of
detecting  PVU  invasive  carcinoma  was  23%
and specificity was 72.2%. On the basis of the
obtained values of sensitivity and specificity,
discrimination power of negative expression
in patients with normal findings in the cervix
was greater than discrimination power of co-
overexpression  of  these  oncogenes  with  the
aim of determining the existence of change of
this type. 
On the basis of high predictive values, it can
be concluded that, statistical wise, all patients
with  co-overexpression  of  bcl-2  and  c-myc
oncogenes will have PVU invasive carcinoma.
Conclusions
The findings presented in this study indi-
cate that the evaluation of co-expression of bcl-
2 and c-myc may provide additional and inde-
pendent prognostic information to predict the
clinical course of cervical cancer. In our study
we confirmed that co-overexpression of these
oncogenes  suggests  with  great  certainty,  at
least  statistically,  that  there  are  malignant
changes in the uterine cervix. However, a more
extensive  series  of  samples  and  additional
tests are required to establish the prognostic
significance of co-expression of  bcl-2 and c-
myc in uterine cervix carcinogenesis.
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